Τόμος 21 (2007) – Τεύχος 1 – Άρθρο 11 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 21 (2007) – Issue 1 – Article 11 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece

pharmakonpress[at]pharmakonpress[.]gr

2.    Robertson J.F.R.: Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treatment Reviews 30: 695-706 (2004)

3.    Hall J.M., McDonnell D.P.: The estrogen receptor p-iso-form (ERp), of the human estrogen receptor modulates ERa transcriptional activity is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578 (1999)

4.    Giguere V.: To ERR in the estrogen pathway. Trends Endocrinol. Metabol. 13: 220-225 (2002)

5.    Termine J.D., Wong M.: Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas 30: 241-245 (1998)

6.    Shintani M.: Which is better choice, estrogen or SERMs in postmenopausal women. Clin. Calcium 14: 1575-1580 (2004)

7     . McDonnell D.P.: The molecular determinants of estrogen receptor pharmacology. Maturitas 48 (Suppl. 1): S7- S12 (2004)

8     . Weinstein R.S., Parfitt M.A., Marcus R., Greenwald M., Grans G., Muchmore D. B.: Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis Int. 14: 814-822 (2003)

9     . Qu Q., Harkonen P.L, Vaananen K. H.: Comparative effects of estrogen and antiestrogens on differentiation of osteoblast in mouse bone marrow culture. J. Cell. Biochem. 73: 500-550 (1999)

10   . Ong D.B., Colley S.M., Norman M.R., Kitazawa S., Tobias J.H.: Transcriptional regulation of a BMP-6 promoter by estrogen receptor alpha . J Bone Miner. Res. 19: 445-454 (2004)

11. Berry M., Metzger D., Chambon P . : Role of the two activating domains of the oestrogen receptor in the cell- type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydrotamoxifen. EMBO J. 9: 2811¬2818 (1990)

12   . McDonnell D.P.: The molecular pharmacology of SERMs. TEM 10: 331-311 (1990)

13   . Albertazzi P., Purdie D.W.: Oestrogen and selective oestrogen receptor modulators (SERMs): current roles in the prevention and treatment of osteoporosis. Best Pract. Res. Clin. Rheumat. 15:451-468 (2001)

14   . Ellsworth A.J., Witt D.M., Dugdale D.C., Oliver L.M.: Mosby’s Medical Drug Reference 2005. Mosby/Elsevier, St. Louis, 2005

15   . Pettersson K, Delaunay F., Gustafsson J.-A.: Estrogen receptor D acts as dominant regulator of estrogen signaling. Oncogene 19: 4970-4978 (2002)

16   . Powles T.J., Hickish T., Kanis J .A., Tidy A., Ashley S.: Effect of tamoxifene on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women . J Clin. Oncol. 14: 78-84 (1996)

17   . Sandberg K.: HRT and SERMs: the good, the bad…and the lovely. Trends Endocrinol. Metabol. 13: 317¬318 (2002)

18   . Cavailles V.: Estrogens and receptors: an evolving concept  Climacteric 5 (Suppl 2): 20-26 (2002)

19   . Stefan J.J., Alenfeld F., Boivin G., Feyen J.H.M., Lakatos P.: Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocrine Regulations 37: 227-240 (2003)

20   . Bryant H. U., Glasebrook A.L., Yanf N.N., Sato M.: An estrogen receptor basis for raloxifene action in bone. J Steroid Bioch. Mol. Biol. 69: 37-44 (1999)

21. Licata A.A., Ciaccia A.V., Wong M., Draper M.W.: Raloxifene: a new choice for treating and preventing osteoporosis. Cleveland Clinic J. Med. 67: 273-280 (2000)

22. Harvey H.A., Kimura M., Hajba A.: Toremifene: an evaluation of its safety profile. The Breast 8, Nov. 2005

23. Maeda T., Ke H Z., Simmons H., Thompson D.: Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin. Calcium 14(10): 85-93 (2004)

24. Perry M.J, Gujral S., Whitworth T., Tobias J.H.: Tamoxifene stimulates cancellous bone formation in long bones of female mice. Endocrinology:    as doi:10.1210/en2004-1114, Dec 2, 2004

25. Ohta H.: Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties. Clin. Calcium 14(10): 73-80 (2004)

26. Buelke-Sam J., Bryant H.U. , Francis P.C.: The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod. Toxicol. 12: 227-221 (1998)

27. Kostoudi S., Kotousi Ch., Myronidou-Tzouveleki M.: Osteoporosis: Treatment and Interactions. Rev. Clin. Pharmacol. Pharmacokinet. (Greek Ed.) 21: 159-195 (2003)

28. Kostoudi S., Kotousi C., Kalousis K., Kougiounmtzis A., Myronidou-Tzouveleki M.: The prevention of osteoporosis: exercise, diet and drugs. Published abstract No 34, in 3rd Congress of German-Greek Academy of Biomedicine, Kavala, May 2004

29. Palmieri C., Lam E .W.-F. , et al.: Correspondence: Value of SERMs in postmenopausal women. Lancet 363: 1477-1478 (2004)

30   . Tou L., Quibria N., Alexander J.M.: Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol. Cell. Endocrinol. 183: 71-79 (2001)

31. Sandberg K.: HRT and SERMs: the good, the bad…and the lovely. Trends Endocrinol. Metabol. 13: 317-318 (2002)

32. Inaba M.: SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects. Ciin. Calcium 14(10): 27-31 (2004)

33. Brama T.M., Teti A., De Luca V., Scandurra R., Spera G., Agnusdel D., Termine J.D., Migliaccio S.: The selective estrogen receptor modulator Raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30: 368-376 (2002)

34. Dodge J.A., Lugar C.W., Cho S., Short L.L., Sato M., Yang N.N., Spangle L.A., Martin MJ., Phillips D.L., Glase-brook A.L., Osborne J.J., Frolik C.A., Bryant H.U.: Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J. Steroid Biochem. Molec. Biol. 61: 97-106 (1997)

35. Bashir A., Mak Y.T., Sankaralingam S., Cheung J., Gowan N.W.A., Grigoriadis A.E., Fogelman I ., Hampson G.: Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70:845-855 (2005)

36. Olivier S., Fillet M . , Malaise M., Piette J., Bours V., Merville M .-P. , Franchimont N .: Sodium nitroprusside- induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene . Biochem. Pharmacol. 69:891-901 (2005)

37. Morii H: Safety profile of raloxifene. Clin. Calcium 14(10): 1570-1574 (2004)

38. Gustrafsson J.-A.: Therapeutic potential of selective estrogen receptor modulators . Curr. Opinion Chem. Biol. 2:508-511 (1998)

39. Scheihofer D.A.: Transcriptional regulation by phytoestrogens in neuronal cell lines . Mol. Cell. Endocrinol. 231: 13-22 (2005)

40.  Azuma K., Inoue S.: Selective estrogen receptor modulator: mechanisms of action and their tissue selectivity. Clin. Calcium 14(10): 12-26 (2004)

41.  Diel P.: Tissue-specific response and molecular mechanisms. Toxicol. Lett. 127: 217-224 (2002)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr